



5<sup>th</sup> March 2026

The ISH Venues, 1 Park Crescent, Regents Park, London.

---

BASL would like to thank the following pharmaceutical companies who provided funding for this meeting.



Our sponsors and supporters of the event have had no influence over or input into the content of the materials used at this meeting including the programme and selection of speakers.

## Programme

### Implementing the Latest HBV & HDV Guidelines into Clinical Care

09:15 – 09:45	Arrival - Registration and coffee
09:45 – 09:50	Introduction <ul style="list-style-type: none"><li>- Prof Patrick Kennedy, (QMUL)</li></ul>
<b>09:45 – 11:05</b>	<b>Session 1 – Clinical Decision Making in HBV: Evidence, Uncertainty &amp; Consensus</b> <b>(Chair: Prof Philippa Matthews)</b>
09:45 – 10:05	Challenges of the EASL HBV CPG 2025 in clinical practice <ul style="list-style-type: none"><li>- Speaker Dr Sabela Lens, Hospital Clínic of Barcelona, Spain</li></ul>
10:05 – 10:25	Treated vs Untreated patients: are we doing the right thing based on recent guidelines? <ul style="list-style-type: none"><li>- Prof Maud Lemoine, (Imperial College, London)</li></ul>
10:25 – 10:45	London HBV consensus recommendations <ul style="list-style-type: none"><li>- Prof Daniel Forton, (City St George's, University of London)</li></ul>
10:45 – 11:05	Panel Discussion & questions
<b>11:05 – 11:25</b>	<b>Coffee and Exhibition</b>

- 11:25 – 12:45**                    **Session 2 – From Risk Stratification to Cure-Readiness in CHB**  
**(Chair: Dr Bo Wang & Dr James Lok)**
- 11:25 – 11:45                    Rethinking Risk in CHB: From ALT Thresholds to Metabolic Comorbidity  
-    *Dr Upkar Gill (QMUL)*
- 11:45 – 12:05                    Are we using nucleos(t)ide analogues optimally – cost effectiveness analysis  
-    *Dr Ricky Sinharay (Royal Berkshire NHS Foundation Trust)*
- 12:05 – 12:25                    Functional cure in CHB: what UK clinicians need to understand now  
-    *Prof Patrick Kennedy, (QMUL)*
- 12:25 – 12:45                    Panel Discussion & questions

**12:45 – 14:00**                    **Lunch and Exhibition**

**14:00 - 15:20**                    **Session 3 – Hepatitis Delta in Practice: From Detection to Treatment**  
**(Chairs: Dr Upkar Gill & Dr Shevanthi Nayagam)**

- 14:00 – 14:20                    Prevalence of Hepatitis Delta & disease burden in the UK  
-    *Dr Ruth Simmons (UKHSA)*
- 14:20 – 14:40                    HDV diagnostics in practice: antibody, RNA, reflex testing & laboratory pathways  
-    *Dr Ivana Carey (Kings College London)*
- 14:40 – 15:00                    Bulevirtide in practice: patient selection, monitoring and service delivery  
-    *Dr Doug MacDonald & AHP (Royal Free Hospital)*
- 15:00 – 15:20                    Panel Discussion & questions

**15:20 – 15:40**                    **Coffee and Exhibition**

**15:40 – 16:50**                    **Session 4 – Viral Hepatitis Care in the NHS: Access, Engagement & Experience**  
**(Chairs: Dr Stuart Flanagan & Dr Monica Desai)**

- 15:40 – 16:00                    Patient perspectives  
-    *Supa Chantschool, HepB companion*
- 16:00 – 16:20                    Challenges and opportunities in increasing hepatitis B diagnosis and linkage to care  
-    *Dave Leeman - UKHSA*
- 16:20 – 16:40                    Viral hepatitis in the liver transformation programme  
-    *Dr Richard Aspinall (Portsmouth Hospitals University NHS Trust)*
- 16:40 – 16:50                    Closing remarks  
-    *Prof. Patrick Kennedy, QMUL*

**For queries, please contact [kim@basl.org.uk](mailto:kim@basl.org.uk) Tel. 01543 442154**